<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00594659</url>
  </required_header>
  <id_info>
    <org_study_id>88268</org_study_id>
    <secondary_id>1R01DA023526-01</secondary_id>
    <secondary_id>1R01DA023526-02</secondary_id>
    <secondary_id>1R01DA023526-03</secondary_id>
    <nct_id>NCT00594659</nct_id>
  </id_info>
  <brief_title>Development and Efficacy Test of Computerized Treatment for Marijuana Dependence</brief_title>
  <official_title>Development and Efficacy Test of Computerized Treatment for Marijuana Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      More US residents are dependent on marijuana than on any other illicit drug, and the number
      enrolled in treatment for marijuana continues to increase such that it is now comparable to
      that for cocaine and heroin. This application seeks to advance the overarching goal to
      develop and disseminate cost-effective treatments for marijuana dependence that can address
      this growing problem.

      The researchers' previous research suggests that an intervention comprising motivational
      enhancement, cognitive-behavioral, and contingency-management components (MET/CBT/CM)
      produces greater rates of successful and durable outcomes than has been demonstrated
      previously. However, three issues relevant to its efficacy and eventual dissemination must be
      confronted. First, the outcomes achieved can only be characterized as modest; many
      individuals do not respond to the treatment and relapse rates remain problematic. Second,
      access is limited by the availability of trained providers. Third, the cost of delivering the
      treatment is higher than more traditional outpatient interventions.

      To address these issues, Specific Aim 1 is to develop and test a computer-assisted version of
      MET/CBT/CM. Computerized treatments have the potential to increase overall effectiveness of
      treatment services by increasing availability of and access to potent treatments, and by
      applying innovative technology to enhance outcomes. During Year 1, the intervention will be
      developed and pilot tested. An interactive program that showed promise in a previous trial
      for opioid dependence will be modified and enhanced to deliver individualized MET/CBT/CM
      using effective computer learning technologies. These technologies and access to the
      MET/CBT/CM program made available via the Internet between treatment sessions and after
      treatment ends have the potential to promote better learning and more use of coping skills,
      which in turn can improve outcomes. During Years 2-4 a randomized trial will provide an
      initial efficacy test of cMET/CBT/CM by comparing it with a brief treatment (MET) and with
      therapist-delivered MET/CBT/CM. Specific Aim 2 is to learn more about how behavioral
      treatments like MET/CBT/CM work by focusing on two putative mechanisms of action examined in
      prior trials: self-efficacy/coping skills and impulsivity/delay discounting. The experimental
      design will provide a unique opportunity to explore such mechanisms in a novel context- where
      the therapist is vs. is not a prominent part of the treatment.

      The proposed project will address the objectives of NIDA's Behavioral and Integrative
      Treatment Development Program by providing research on technology-assisted treatment that
      attempts to make treatment delivery less complex, easier to access, and less costly - while
      retaining or improving its effectiveness. Findings will inform future studies designed to
      refine the technology and how it is applied; conduct more definitive effectiveness testing;
      test generality to other populations including adolescents; and to further advance
      translation to community settings.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Consecutive Weeks of Marijuana Abstinence</measure>
    <time_frame>From the start of treatment through the end of the active treatment period, i.e., 12 weeks.</time_frame>
    <description>Longest period of marijuana abstinence achieved during the 12-week treatment period documented by urine testing and self-report.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Point Prevalence Abstinence Post Treatment</measure>
    <time_frame>9 months (from the end of treatment to 9 months post-treatment).</time_frame>
    <description>Percent of participants that were marijuana abstinent based on urine toxicology testing at each follow up assessment across 9 month follow up period ( at the end of treatment, at 3-months, 6-months, and 9 months post the end of treatment).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Marijuana Abuse and Dependence</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Therapist delivered cognitive behavioral treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Computerized Cognitive Behavioral treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Motivational enhancement therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Psychotherapy</intervention_name>
    <description>Nine session treatment</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Computerized Psychotherapy</intervention_name>
    <description>Nine session computer delivered treatment</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Motivational enhancement therapy</intervention_name>
    <description>Two session treatment</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Meet criteria for current DSM-IV diagnosis of marijuana abuse or dependence

          -  Report use of marijuana on at least 40 of the past 90 days

          -  Severe psychological distress

        Exclusion Criteria:

          -  Current dependence on alcohol or any other drug (except nicotine)

          -  Participation in treatment for alcohol/drug problem

          -  A legal status which will interfere with participation

          -  Plans to move out of the area in the next 12 months

          -  Living with someone who is already enrolled in the project

          -  Not living within approximately 30 miles of the research site

          -  Not being fluent in English
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan J Budney, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Geisel School of Medicine at Dartmouth</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2008</study_first_submitted>
  <study_first_submitted_qc>January 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2008</study_first_posted>
  <results_first_submitted>April 16, 2013</results_first_submitted>
  <results_first_submitted_qc>December 3, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 4, 2013</results_first_posted>
  <last_update_submitted>December 3, 2013</last_update_submitted>
  <last_update_submitted_qc>December 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Marijuana</keyword>
  <keyword>Treatment</keyword>
  <keyword>Behavioral</keyword>
  <keyword>Computer</keyword>
  <keyword>Internet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment opened in November 2008 and closed in May 2011. Recruitment practices included newspaper and radio advertisements, flyers, and posters distributed in local businesses and agencies. The study took place at an outpatient psychiatry clinic.</recruitment_details>
      <pre_assignment_details>Participants were excluded from trial prior to group assignment for at least one of the following:no evidence of marijuana use in at least 40 of the past 90 days prior to enrollment,participant met criteria for dependence on alcohol or illicit drugs,evidence of illicit drug use or K-2 use,interfering medical/psychiatric illness,or active refusal.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1-MET/CBT/CM</title>
          <description>Therapist delivered motivational enhancement therapy plus cognitive behavioral therapy plus contingency management (tMET/CBT/CM)
Psychotherapy : Nine session treatment (wks 1-8 and wk 12)
2x/wk urine drug testing
Contingency Management voucher program</description>
        </group>
        <group group_id="P2">
          <title>2-cMET/CBT/CM</title>
          <description>Computer-delievered (c) MET/CBT/CM treatment
Computerized Psychotherapy : Nine session computer delivered treatment
2 times per week urine drug testing</description>
        </group>
        <group group_id="P3">
          <title>3-tMET</title>
          <description>Motivational enhancement therapy
Motivational enhancement therapy : Two session treatment
2x/wk urine drug testing
non-contingent vouchers</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1-MET/CBT/CM</title>
          <description>Therapist delivered motivational enhancement therapy plus cognitive behavioral therapy plus contingency management (tMET/CBT/CM)
Nine weekly therapy sessions delivered in weeks 1-8 and week 12
2 times per week urine drug testing
Contingency management program delivered monetary-based incentives contingent on each marijuana-negative urine toxicology test.</description>
        </group>
        <group group_id="B2">
          <title>2-cMET/CBT/CM</title>
          <description>Computer-delievered (c) MET/CBT/CM treatment
Computer delivered nine MET/CBT sessions during weeks 1-8 and week 12. therapist delivered 3 brief supportive counseling sessions during weeks 1, 4, and 12.
2 times per week urine drug testing.
Contingency management program delivered monetary-based incentives contingent on each marijuana-negative urine toxicology test.</description>
        </group>
        <group group_id="B3">
          <title>3-tMET</title>
          <description>Therapist delivered motivational enhancement therapy (tMET)
Two session treatment with sessions delivered during weeks 1 and 4.
Two times per week urine drug testing.
Non-contingent incentives delivered for attending each urine testing appointment.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.7" spread="11.06"/>
                    <measurement group_id="B2" value="34.87" spread="11.07"/>
                    <measurement group_id="B3" value="35" spread="8.95"/>
                    <measurement group_id="B4" value="34.85" spread="10.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Point prevalence abstinence</title>
          <description>Total percentage column is not accurate because it is automatically summed, which results in an invalid number.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12.5"/>
                    <measurement group_id="B4" value="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Consecutive Weeks of Marijuana Abstinence</title>
        <description>Longest period of marijuana abstinence achieved during the 12-week treatment period documented by urine testing and self-report.</description>
        <time_frame>From the start of treatment through the end of the active treatment period, i.e., 12 weeks.</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>1-tMET/CBT/CM</title>
            <description>Therapist delivered cognitive behavioral treatment
Psychotherapy : Nine session treatment</description>
          </group>
          <group group_id="O2">
            <title>2-cMET/CBT/CM</title>
            <description>Computerized Cognitive Behavioral treatment
Computerized Psychotherapy : Nine session computer delivered treatment</description>
          </group>
          <group group_id="O3">
            <title>3-tMET</title>
            <description>Motivational enhancement therapy
Motivational enhancement therapy : Two session treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Consecutive Weeks of Marijuana Abstinence</title>
          <description>Longest period of marijuana abstinence achieved during the 12-week treatment period documented by urine testing and self-report.</description>
          <population>Intent to Treat</population>
          <units>consecutive weeks of abstinence</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.55" spread="4.39"/>
                    <measurement group_id="O2" value="2.82" spread="4.21"/>
                    <measurement group_id="O3" value="0.78" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparison; non-parametric tests performed because of non-normal distribution</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>accelerated bootstrapping</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>pairwise comparison; non-parametric analysis</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; .05</p_value>
            <method>accelerated bootstrapping</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>nonparametric pairwise comparison; non-normal distribution</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; 0.05</p_value>
            <method>accelerated bootstrapping</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Point Prevalence Abstinence Post Treatment</title>
        <description>Percent of participants that were marijuana abstinent based on urine toxicology testing at each follow up assessment across 9 month follow up period ( at the end of treatment, at 3-months, 6-months, and 9 months post the end of treatment).</description>
        <time_frame>9 months (from the end of treatment to 9 months post-treatment).</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>1-tMET/CBT/CM</title>
            <description>Therapist delivered cognitive behavioral treatment
Psychotherapy : Nine session treatment</description>
          </group>
          <group group_id="O2">
            <title>2-cMET/CBT/CM</title>
            <description>Computerized Cognitive Behavioral treatment
Computerized Psychotherapy : Nine session computer delivered treatment</description>
          </group>
          <group group_id="O3">
            <title>3-tMET</title>
            <description>Motivational enhancement therapy
Motivational enhancement therapy : Two session treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Point Prevalence Abstinence Post Treatment</title>
          <description>Percent of participants that were marijuana abstinent based on urine toxicology testing at each follow up assessment across 9 month follow up period ( at the end of treatment, at 3-months, 6-months, and 9 months post the end of treatment).</description>
          <population>Intent to Treat</population>
          <units>pecentage of participants abstinent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>End of Treatment (ETX) Abstinence Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.8"/>
                    <measurement group_id="O2" value="46.7"/>
                    <measurement group_id="O3" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-Months Post Treatment Abstinence Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7"/>
                    <measurement group_id="O2" value="36.7"/>
                    <measurement group_id="O3" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-months Post Treatment Abstinence Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2"/>
                    <measurement group_id="O2" value="36.7"/>
                    <measurement group_id="O3" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9-months Post Treatment Abstinence Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3"/>
                    <measurement group_id="O2" value="23.3"/>
                    <measurement group_id="O3" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>pairwise comparisons among groups across 4 follow-up timepoints</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.05</p_value>
            <method>piecewise mixed model with logit link an</method>
            <method_desc>Performed across all assessments.</method_desc>
            <param_type>Slope</param_type>
            <param_value>3.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.69</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Slope and p-value above are for group 1: baseline to ETX. Group 3 vs. Group 1 baseline to ETX slope, p &lt; 0.05. All other pairwise comparisons p &gt; 0.05.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1-MET/CBT/CM</title>
          <description>Therapist delivered motivational enhancement therapy plus cognitive behavioral therapy plus contingency management (tMET/CBT/CM)
Psychotherapy : Nine session treatment (wks 1-8 and wk 12)
2x/wk urine drug testing
Contingency Management voucher program</description>
        </group>
        <group group_id="E2">
          <title>2-cMET/CBT/CM</title>
          <description>Computer-delievered (c) MET/CBT/CM treatment
Computerized Psychotherapy : Nine session computer delivered treatment
2 times per week urine drug testing</description>
        </group>
        <group group_id="E3">
          <title>3-tMET</title>
          <description>Motivational enhancement therapy
Motivational enhancement therapy : Two session treatment
2x/wk urine drug testing
non-contingent vouchers</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alan J. Budney, PhD Principal Investigator</name_or_title>
      <organization>Geisel School of Medicine at Dartmouth College</organization>
      <phone>855-290-2822</phone>
      <email>Alan.J.Budney@dartmouth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

